share_log

Novavax (NASDAQ:NVAX) Downgraded by JPMorgan Chase & Co.

Novavax (NASDAQ:NVAX) Downgraded by JPMorgan Chase & Co.

摩根大通下调了Novavax(纳斯达克股票代码:NVAX)的评级
kopsource ·  2022/09/25 15:41

JPMorgan Chase & Co. downgraded shares of Novavax (NASDAQ:NVAX – Get Rating) from a neutral rating to an underweight rating in a report released on Thursday, The Fly reports. They currently have $27.00 price target on the biopharmaceutical company's stock, down from their prior price target of $132.00.

摩根大通下调了的股票评级 Novavax(纳斯达克股票代码:NVAX — 获取评级) The Fly报道,在周四发布的报告中,从中性评级到减持评级。他们目前对这家生物制药公司股票的目标股价为27.00美元,低于之前的132.00美元的目标股价。

NVAX has been the topic of a number of other reports. Cantor Fitzgerald upped their price target on shares of Novavax from $146.00 to $168.00 in a research note on Wednesday, June 8th. Cowen lowered their price target on shares of Novavax from $150.00 to $110.00 and set an outperform rating on the stock in a research note on Tuesday, August 9th. B. Riley lowered their price objective on shares of Novavax from $181.00 to $171.00 in a research note on Friday, July 22nd. Finally, Cowen lowered their price objective on shares of Novavax to $110.00 in a research note on Monday, August 15th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and a consensus target price of $128.25.

NVAX 一直是许多其他报告的主题。坎托·菲茨杰拉德在6月8日星期三的一份研究报告中将Novavax股票的目标股价从146.00美元上调至168.00美元。Cowen在8月9日星期二的一份研究报告中将Novavax股票的目标股价从150.00美元下调至110.00美元,并对该股设定了跑赢大盘的评级。B. Riley在7月22日星期五的一份研究报告中将Novavax股票的目标股价从181.00美元下调至171.00美元。最后,Cowen在8月15日星期一的一份研究报告中将Novavax股票的目标股价下调至110.00美元。两位投资分析师对该股进行了卖出评级,一位发布了持有评级,五位投资分析师对该公司的股票给出了买入评级。根据MarketBeat的数据,该股目前的共识评级为持有,共识目标价为128.25美元。

Get
得到
Novavax
Novavax
alerts:
警报:

Novavax Stock Performance

Novavax 股票表现

Shares of NVAX opened at $21.00 on Thursday. The stock has a market capitalization of $1.64 billion, a P/E ratio of -1.08, a P/E/G ratio of 0.10 and a beta of 1.65. The company's fifty day moving average is $41.22 and its two-hundred day moving average is $52.06. Novavax has a 1 year low of $20.46 and a 1 year high of $257.30.

NVAX的股票周四开盘价为21.00美元。该股的市值为16.4亿美元,市盈率为-1.08,市盈率为0.10,beta值为1.65。该公司的五十天移动平均线为41.22美元,其两百天移动平均线为52.06美元。Novavax的1年低点为20.46美元,为1年来的最高水平,为257.30美元。

Novavax (NASDAQ:NVAX – Get Rating) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($6.53) earnings per share for the quarter, missing analysts' consensus estimates of $5.51 by ($12.04). Novavax had a negative return on equity of 572.54% and a negative net margin of 114.32%. The company had revenue of $186.00 million for the quarter, compared to analyst estimates of $1.02 billion. During the same period last year, the company earned ($4.75) earnings per share. The business's revenue for the quarter was down 37.6% compared to the same quarter last year. Sell-side analysts predict that Novavax will post 6.09 EPS for the current year.
Novavax(纳斯达克股票代码:NVAX — 获取评级)最后一次公布其季度财报是在8月8日星期一。这家生物制药公司公布了本季度每股收益(6.53美元),低于分析师普遍估计的5.51美元(12.04美元)。Novavax的负股本回报率为572.54%,净利润率为负114.32%。该公司本季度的收入为1.86亿美元,而分析师的估计为10.2亿美元。去年同期,该公司的每股收益(4.75美元)。与去年同期相比,该业务本季度的收入下降了37.6%。卖方分析师预测,Novavax今年将公布每股收益6.09美元。

Institutional Investors Weigh In On Novavax

机构投资者对 Novavax 进行了权衡

Several hedge funds have recently modified their holdings of the company. B. Riley Wealth Management Inc. boosted its stake in shares of Novavax by 22.0% during the 2nd quarter. B. Riley Wealth Management Inc. now owns 5,044 shares of the biopharmaceutical company's stock worth $259,000 after purchasing an additional 909 shares during the last quarter. Captrust Financial Advisors boosted its stake in shares of Novavax by 83.3% during the 2nd quarter. Captrust Financial Advisors now owns 6,703 shares of the biopharmaceutical company's stock worth $345,000 after purchasing an additional 3,047 shares during the last quarter. ExodusPoint Capital Management LP boosted its stake in shares of Novavax by 212.8% during the 2nd quarter. ExodusPoint Capital Management LP now owns 21,296 shares of the biopharmaceutical company's stock worth $1,095,000 after purchasing an additional 14,487 shares during the last quarter. Worldquant Millennium Advisors LLC boosted its stake in shares of Novavax by 309.1% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 142,745 shares of the biopharmaceutical company's stock worth $7,341,000 after purchasing an additional 107,853 shares during the last quarter. Finally, Centiva Capital LP boosted its stake in shares of Novavax by 1,201.1% during the 2nd quarter. Centiva Capital LP now owns 103,397 shares of the biopharmaceutical company's stock worth $5,317,000 after purchasing an additional 112,787 shares during the last quarter. 42.63% of the stock is owned by institutional investors and hedge funds.

几家对冲基金最近修改了对该公司的持股。B. Riley Wealth Management Inc. 在第二季度将其持有的Novavax股票的股份增加了22.0%。B. Riley Wealth Management Inc. 在上个季度又购买了909股股票后,现在拥有这家生物制药公司的5,044股股票,价值25.9万美元。Captrust Financial Advisors在第二季度将其在Novavax的股票中的股份增加了83.3%。Captrust Financial Advisors在上个季度又购买了3,047股股票后,现在拥有这家生物制药公司的6,703股股票,价值34.5万美元。ExodusPoint Capital Management LP在第二季度将其在Novavax的股票中的股份增加了212.8%。ExodusPoint Capital Management LP在上个季度又购买了14,487股股票后,现在拥有这家生物制药公司的21,296股股票,价值1,09.5万美元。Worldquant Millennium Advisors LLC在第二季度将其在Novavax的股份增加了309.1%。Worldquant Millennium Advisors LLC在上个季度又购买了107,853股股票后,现在拥有这家生物制药公司的142,745股股票,价值7,341,000美元。最后,Centiva Capital LP在第二季度将其在Novavax的股份增加了1,201.1%。Centiva Capital LP在上个季度又购买了112,787股股票后,现在拥有这家生物制药公司的103,397股股票,价值5,317,000美元。该股的42.63%由机构投资者和对冲基金持有。

About Novavax

关于 Novavax

(Get Rating)

(获取评级)

Novavax, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.

Novavax, Inc是一家生物技术公司,专注于疫苗的发现、开发和商业化,以预防严重传染病和满足健康需求。该公司的候选疫苗包括NVx-CoV2373,这是一种正在进行两项III期试验、一项IIb期试验和一项I/II期试验的冠状病毒候选疫苗;nanoFlu,一种正在进行三期临床试验的纳米颗粒季节性四价流感候选疫苗;以及呼吸道合胞病毒 (RSV) 融合 (F) 蛋白纳米颗粒候选疫苗ResVax。

Recommended Stories

推荐故事

  • Get a free copy of the StockNews.com research report on Novavax (NVAX)
  • Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
  • MarketBeat: Week in Review 9/19 – 9/23
  • Why Does Tesla Stock Remain Resilient?
  • Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
  • Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
  • 免费获取 StockNews.com 关于 Novavax (NVAX) 的研究报告的副本
  • 华尔街对Datadog的热情会带来巨大收益吗?
  • MarketBeat:本周回顾 9 月 19 日至 9 月 23 日
  • 为什么特斯拉股票保持弹性?
  • 小型科技公司的裁员是房地产股的领头羊吗?
  • 好市多的盈利后价格疲软是买入的好时机吗?

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Novavax Daily 的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收Novavax及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发